Physician profile
Stuart Ross Ball
NPI 1528479987
$3,462.67
in general payments reported to CMS, 2019-2025
19 companies · $665 in 2025
The $665 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $926 · 2020: $62.84 · 2021: $282 · 2022: $287 · 2023: $661 · 2024: $578 · 2025: $665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,884 · Education: $20.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,883.83 |
| Education | $20.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $704.75 | 2019 | |
| Abbvie INC. | $650.23 | 2022-2025 | Durysta, Xen Glaucoma Treatment System, Ozurdex |
| Regeneron Healthcare Solutions, INC. | $635.23 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $413.64 | 2022-2025 | Vabysmo, Susvimo |
| Sight Sciences, INC. | $248.37 | 2023-2025 | Omni Surgical System, Sion Surgical Instrument |
| Alimera Sciences, INC. | $153.72 | 2019-2024 | Iluvien, Yutiq |
| Novartis Pharmaceuticals Corporation | $129.33 | 2019-2021 | |
| Allergan, INC. | $79.29 | 2021-2022 | |
| Iridex Corporation | $75.92 | 2023 | |
| Dutch Ophthalmic, USA | $73.04 | 2025 | Tissueblue, Eva, Combined Machine |
| Astellas Pharma US INC | $70.12 | 2025 | Izervay |
| Dompe US, INC. | $54.06 | 2025 | Oxervate |
| Ani Pharmaceuticals, INC. | $48.66 | 2025 | Iluvien, Purified Cortrophin Gel, Yutiq |
| Alcon Vision LLC | $37.58 | 2022 | |
| Coherus Oncology, INC. | $19.49 | 2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $18.94 | 2025 | |
| Apellis Pharmaceuticals, INC. | $18.18 | 2024 | Syfovre |
| Eyepoint US, INC. | $16.23 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $15.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Ball listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.